Osteoprotegerin in relation to insulin resistance and blood lipids in sub-Saharan African women with and without abdominal obesity

Diabetology & Metabolic Syndrome

Jean François Gautier⁶  Laurent Serge Etoundi Ngoa³  Philippe Boudou⁶  Jean Jacques N. Noubiap⁵  Mickael Essouma²  Eugene Sobngwi⁴  Clarisse Noël Ayina Ayina¹ 

[1] Department of Animal Science, Faculty of Science, University of Douala, Douala, Cameroon;Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon;Department of Animal Science, Higher Teacher’s Training College, University of Yaoundé I, Yaoundé, Cameroon;National Obesity Center, Yaoundé Central Hospital, Yaoundé, Cameroon;Medical Diagnostic Center, Yaoundé, Cameroon;Department of Diabetes and Endocrinology, Saint-Louis Hospital, Public Assistance - Paris Hospitals, University Paris-Diderot Paris-7, Paris, France

关键词: Sub-Saharan Africans;    Obesity;    Lipids;    Insulin resistance;    Osteoprotegerin;   

Others  :  1211821
DOI  :  10.1186/s13098-015-0042-3

 received in 2015-02-21, accepted in 2015-05-13,  发布年份 2015

【 摘 要 】

Background

Osteoprotegerin (OPG), a soluble member of the tumor necrosis factor receptor superfamily that inhibits bone resorption, has been suggested as a potential marker of cardiovascular risk. This study aimed to assess the relationship between insulin resistance, lipid profile and OPG levels in obese and non-obese sub-Saharan African women.

Methods

Sixty obese (44) and non-obese (16) volunteer women aged 18 to 40 years were recruited in this cross-sectional study. Their clinical (age, height, weight, waist circumference, systolic and diastolic blood pressures) and biochemical parameters (fasting blood glucose, total cholesterol, high density lipoprotein-cholesterol (HDL-C)) were measured using standard methods. Insulin levels were measured using an electrochemiluminescence immunoassay, while OPG levels were measured using the ELISA technique. Low density lipoprotein-cholesterol (LDL-C), body mass index (BMI) and Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) were calculated using standard methods. Abdominal obesity was defined as a waist circumference ≥ 80 cm.

Results

OPG levels were higher in obese than in normal subjects, though the difference was not significant (p = 0.9). BMI, waist circumference, percent body fat and systolic blood pressure were significantly higher in obese than in non-obese subjects (p < 0.05). In these subjects, only age significantly correlated with OPG levels (r = 0.831, p = 0.003), while none of the anthropometric nor metabolic parameter did, even after adjustment for age. In obese subjects, OPG levels fairly correlated with HDL-C (r = 0.298, p = 0.058), and significantly correlated with HOMA-IR (r = −0.438, p = 0.018). After adjustment for age, OPG levels remained negatively correlated to HOMA-IR (r = −0.516, p = 0.020) and LDL-C (r = −0.535, p = 0.015) and positively correlated to HDL-C (r = 0.615, p = 0.004). In multiple linear regression analysis, age was a main determinant of OPG levels in non-obese (β = 0.647, p = 0.006) and obese (β = 0.356, p = 0.044) women. HDL-C was also associated to OPG levels in obese women (β = 0.535, p = 0.009).

Conclusion

The positive correlation of OPG with HDL-C and HOMA-IR, and its negative correlation with LDL-C suggest that it may be a marker of insulin sensitivity/resistance and atherogenic risk in obese African women.

【 授权许可】

   
2015 Ayina Ayina et al.; licensee BioMed Central.

【 参考文献 】

• [1]Hofbauer LC, Heufelder AE: Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab 2000, 85:2355-63.
• [2]Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 1998(93):165-76.
• [3]Kwon BS, Wang S, Udagawa N, Haridas V, Lee ZH, Kim KK, et al.: TR1, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998, 12:845-54.
• [4]Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, et al.: Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice. Circulation 2008, 117(3):411-20.
• [5]Moldovan D, Kacso IM, Rusu C, Potra A, Bondor CI, Moldovan I, et al.: Role of osteoprotegerin in vascular disorders of the end-stage renal disease patients. Biomarkers 2015, 15:1-7.
• [6]Delgado-Frías E, López-Mejias R, Genre F, Ubilla B, Gómez Rodríguez-Bethencourt MA, González-Díaz A, et al. Relationship between endothelial dysfunction and osteoprotegerin, Vitamin D, and bone mineral density in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015. [Epub ahead of print].
• [7]Kalaycıoğlu E, Gökdeniz T, Aykan AÇ, Hatem E, Gürsoy MO, Ören A, et al.: Osteoprotegerin is associated with subclinical left ventricular systolic dysfunction in diabetic hypertensive patients: a speckle tracking study. Can J Cardiol 2014, 30(12):1529-34.
• [8]Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, et al.: Osteoprotegerin predicts progression of chronic heart failure: results from CORONA. Circulation 2011, 4(2):145-52.
• [9]Aramburu-Bodas O, García-Casado B, Salamanca-Bautista P, Guisado-Espartero ME, Arias-Jiménez JL, Barco-Sánchez A, et al. Relationship between osteoprotegerin and mortality in decompensated heart failure with preserved ejection fraction. J Cardiovasc Med (Hagerstown). 2014. [Epub ahead of print].
• [10]Gannage-Yared MH, Yaghi C, Habre B, Khalife S, Noun R, Germanos-Haddad M, et al.: Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol 2008, 158(3):353-9.
• [11]López-Mejias R, Ubilla B, Genre F, Corrales A, Hernández JL, Ferraz-Amaro I, et al.: Osteoprotegerin concentrations relate independently to established cardiovascular disease in rheumatoid arthritis. J Rheumatol 2015, 42(1):39-45.
• [12]Gannage-Yared MH, Fares F, Semaan M, Khalife S, Jambart S: Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006, 64:652-8.
• [13]Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.
• [14]Bjerre M: Osteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications. Springerplus 2013, 2:658. BioMed Central Full Text
• [15]Park JS, Cho MH, Ji NS, Yoo JS, Ahn CVV, Cha BS, et al.: Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. Eur J Endocrinol 2011, 164:69-74.
• [16]Ayina Ayina CN, Boudou P, Fidaa I, Balti EV, Sobngwi E, Etoundi Ngoa LS, et al.: Osteoprotegerin is not a determinant of Metabolic syndrom in sub-Saharan Africans after age-adjustment. Ann Endocrinol (Paris) 2014, 75(3):165-70.
• [17]Van Campenhout A, Golledge J: Osteoprotegerin, vascular calcification and atherosclerosis. Atherosclerosis 2009, 204(2):321-9.
• [18]Kiechl S, Werner P, Knoflach M, Furtner M, Willeit J, Schett G: The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Rev Cardiovasc Ther 2006, 4:801-811.
• [19]Gotto AM Jr: Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? Trans Am Clin Clim Assoc 2011, 122:256-89.
• [20]Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, et al.: Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE−/− mice. Arterioscler Thromb Vasc Biol 2006, 26:2117-2124.
• [21]Antuna-Puente B, Disse E, Rabasa-Lhoret R, Laville M, Capeau J, Bastard JP: How can we measure insulin sensitivity/resistance? Diabetes Metab 2011, 37:179-188.
• [22]Sobngwi E, Kengne AP, Echouffo-Tcheugui JB, Choukem S, Sobngwi-Tambekou J, Balti EV, et al.: Fasting insulin sensitivity indices are not better than routine clinical variables at predicting insulin sensitivity among Black Africans: a clamp study in sub-Saharan Africans. BMC Endocr Disord 2014, 14:65. BioMed Central Full Text